Hydroxychloroquine and Azithromycin as Prophylaxis for Healthcare Workers Dealing With COVID19 Patients

• Medical doctors, Nurses and Respiratory therapists caring for COVID-19 patients in ER and ICU and dedicated COVID19 units.
• Age between 18 and 70 years old.
• Male or non-pregnant, non- lactating female.
• Availability for follow up by phone.
• Willing to participate and provide signed informed consent.

Exclusion Criteria:

• Subjects with a history of retinopathy, sickle cell disease or trait, psoriasis, or porphyria.
• Subjects who take certain prescribed or over the counter (OTC) concomitant medication including ampicillin, cimetidine, digoxin, statins, cyclosporine, warfarin, fluconazole, within 2 weeks of dosing start, and during the duration of the study.
• Current Symptoms of Fever, Cough, or Shortness of Breath.
• PCR confirmed positive test of COVID-19.
• Weight \< 40 kg.
• Pregnant (positive β-human chorionic gonadotropin test, β-HCG) or lactating female at the screening.
• Allergy to any of the study medications.
• History of splenectomy.
• Infection with hepatitis B or C viruses.
• Chronic or active neurologic disease including seizure disorder and chronic migraine headaches.

• Any abnormal baseline laboratory screening tests listed below

  • Aspartate aminotransferase (AST) or alanine aminotransferase (ALT)above twice the upper limit of normal for the reference lab.
  • Creatinine above the normal range.
  • Hemoglobin for males \<12.5 g/dl and females \<10.5 g/dl.
  • Platelet count of \<150 X 103/L.
  • Total white blood cell (WBC) count out of normal range Note: If screening lab values are out of the normal range but are expected to be temporary (e.g. due to dehydration), they may be re-assessed one more time at the discretion of the investigator.
• An abnormal baseline screening ECG suggestive of cardiac disease as determined by a clinical investigator. QTcF of >450 msec for males and >470 msec for females.
• Any other significant finding that based on the judgment of the PI would increase the risk of having an adverse outcome from participating in this study
• Subjects known to have a mental illness
• Subjects who have Skin disorders (including rash, dermatitis, and psoriasis)
• Hematological disease.
• Cardiovascular disease.
• G6PD deficiency.
• Lactose intolerance.